Choose a competitor if you need insurance billing, brand-name medication options, structured coaching, or more established patient reviews to evaluate
Zepbound is FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity
Some GLP-1 medications have evidence of cardiovascular risk reduction in specific patient groups
Electrolyte loss: Vomiting or diarrhea can lead to electrolyte loss
In addition to GLP-1/GIP/GCG receptors tri-agonists, there are also triagonists targeting Xenopus GLP-1/GCG/Cholecystokinin-2 (CCK2) receptors [107], GLP-1/GCG/ neuropeptide Y 2 receptors [108], and GLP-1R, neuropeptide Y1, and neuropeptide Y2 receptors [109]
Generally, GLP-1 agonist medications are FDA approved for adults aged 18 years and older with certain body mass indexes (BMI) (typically a BMI of 30 or above, or a BMI of 27 or above if you have a weight-related health condition such as hypertension, high cholesterol, weight-related anxiety, liver disease, sleep apnea or PCOS)
